The Company is a clinical-stage immunology focused biopharmaceutical company developing innovative treatments to transform the lives of patients.
The Company locates its headquarters in Singapore and set up outposts in Taiwan, China and Australia to create a cross-regional platform. Through this platform, the Company is authorized to introduce pharmaceuticals from international pharmaceutical factories and biotechnology companies and it is also involved in the later production and clinical activities. The Company owns five products at the research and development stage which are mainly targeted at indications including biliary tract, gastric, breast and colorectal cancers.
The Company has only one reportable operating segment.
HISTORY
2014 The Company was incorporated in the Cayman Islands on June 23 2014.
2017 The Company was listed on OTC on June 1, 2017.
2020 The Company was delisted on September 16 2020.
2022 On September 29, 2022, the Company transferred to The Nasdaq Capital Market and continued trading under the same trading symbol “ASLN”.
Headquarters
83 Clemenceau Avenue, 12-03 Ue Square
Singapore; Singapore;
Postal Code: 239920
Contact Details: Purchase the Aslan Pharmaceuticals Ltd. report to view the information.
Website: http://www.aslanpharma.com
EMIS company profiles are part of a larger information service which combines company, industry and country data and analysis for over 145 emerging markets.
Request a demo of the EMIS serviceTo view more information, Request a demonstration of the EMIS service